Tg Therapeutics, Inc. (TGTX) Stock Price & Analysis
Tg Therapeutics, Inc. (TGTX) rose 5.91% to USD 43.37 as of June 10, 2026 at 00:51 UTC, according to Nexqual real-time market data.
TGTX last closed at USD 40.95; the session ranged USD 41.55–43.45 on volume of 2,115,282 shares. Market capitalization is $6.64B, with a 52-week range of USD 25.28–44.65 (NCM). Source: Nexqual, June 10, 2026 at 00:51 UTC.
Key Statistics (as of June 10, 2026 at 00:51 UTC)
| Price | USD 43.37 |
|---|---|
| Change | ▲ 5.91% (up) |
| Previous Close | USD 40.95 |
| Open | USD 42.49 |
| Day Range | USD 41.55 – 43.45 |
| 52-Week Range | USD 25.28 – 44.65 |
| Volume | 2,115,282 shares |
| Market Cap | $6.64B |
| Exchange | NCM |
Technical Analysis (TGTX)
Nexqual's technical model rates TGTX "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:51 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.89 (neutral) |
| vs SMA50 | Above (USD 37.41) |
| MACD | 0.93 (positive) |
Analyst Ratings (TGTX)
Wall Street analysts rate TGTX "Buy" based on 7 analysts, with a mean price target of USD 48 (range USD 17–70), per Nexqual as of June 10, 2026 at 00:51 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 48 |
| High Target | USD 70 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 7 / 1 / 1 |
Earnings (TGTX)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 0.43 |
| Revenue Estimate | $228.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.18 vs est 0.28 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.33 ▼ miss |
| 2025-09-30 | USD 0.16 vs est 0.22 ▼ miss |
| 2025-06-30 | USD 0.17 vs est 0.29 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financials & Fundamentals (TGTX)
| Total Revenue | $700.35M |
|---|---|
| Revenue Growth (YoY) | +69.60% |
| Gross Margin | +83.05% |
| Operating Margin | +16.98% |
| Profit Margin | +65.95% |
| ROE | +112.60% |
| Debt / Equity | 129.23 |
| Current Ratio | 5.81 |
| Total Cash | $514.43M |
| Total Debt | $753.56M |
| Free Cash Flow | $-30.16M |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financial Health Score (TGTX)
Nexqual rates Tg Therapeutics, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:51 UTC.
| Growth | Strong — Revenue +87% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 83%, operating 17% |
| Balance Sheet | Mixed — $514M cash vs $754M debt |
| Cash Flow | Weak — FCF negative: -$30M, burning cash |
| Efficiency | Strong — ROE 113%, ROA 8.6% |
Ownership (TGTX)
| Insider Ownership | +7.47% |
|---|---|
| Institutional Ownership | +70.24% |
| Shares Outstanding | 153.08M |
| Float | 135.10M |
| Short % of Float | +26.61% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Leadership (TGTX)
Tg Therapeutics, Inc. is led by Michael S. Weiss Esq. (age 59), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 00:51 UTC.
| Chairman, CEO & President | Michael S. Weiss Esq. (age 59) |
|---|---|
| CFO, Corporate Secretary & Treasurer | Sean A. Power (age 43) |
| Senior Vice President of Corporate Communications | Jenna Bosco |
Major Backers & Investors (TGTX)
Notable institutional backers of Tg Therapeutics, Inc. include Soleus Capital Management, L.P., ClearBridge Investments, LLC, Goldman Sachs, according to Nexqual as of June 10, 2026 at 00:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 2.63% |
| ClearBridge Investments, LLC | 2.1% |
| Goldman Sachs | 1.49% |
| Congress Asset Management Co | 1.42% |
| Jane Street Group, LLC | 1.33% |
| Fidelity | 0.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 22.18% |
| Vanguard Group | 18.24% |
| State Street | 7.86% |
| Geode Capital | 2.29% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
From Tg Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- To this end, we seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees and consultants.
- Before marketing in the U.S., any drug that we develop must undergo rigorous pre-clinical testing and clinical trials and an extensive regulatory review and approval process implemented by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) and, in the case of biologics, the Public Health Service Act.
- Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our product candidates, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.   We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors.
- This knowledge, trade secrets, proprietary information and experience we call "know-how." To help protect our proprietary know-how, which is not patentable, and for inventions for which patents may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protect our interests.
Partnerships
- Commercialization of BRIUMVI   In August 2023, we entered into a Commercialization Agreement with Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, for the ex-U.S. commercialization of BRIUMVI.
- During this 12-year period, which extends until December 2034, a biosimilar product that references our BRIUMVI product cannot be approved.  ​ Azer-Cel (allogeneic CD19 CAR T)   Pursuant to our license agreement with Precision, we have an exclusive license to develop and commercialize Precision's azer-cel for the treatment of autoimmune and other non-oncology diseases and conditions as well as a non-exclusive license to manufacture azer-cel.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | USD 245.64 | ▲ 5.73% |
| AUPH | Aurinia Pharmaceuticals Inc | USD 15.78 | ▼ 0.38% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 3.88 | ▼ 8.27% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 476.89 | ▼ 2.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:51 UTC. This page is informational and not investment advice.